Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | CTH | P32929 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22239425 | 0.83 | NOS3 (0.42) | NOS3NOS1NOS2CTHMETAP2 | |
| SCHEMBL8190911 | 0.83 | NOS3 (0.38) | NOS3NOS1NOS2CTHMETAP2 | |
| SCHEMBL661299 | 0.77 | — | — | |
| SCHEMBL6758747 | 0.77 | NFE2L2 (0.46) | — | |
| SCHEMBL24440652 | 0.76 | NOS3 (0.39) | NOS3NOS1NOS2CTHMETAP2 | |
| SCHEMBL29426573 | 0.76 | — | — | |
| SCHEMBL21730387 | 0.76 | — | — | |
| SCHEMBL159686 | 0.76 | — | — | |
| SCHEMBL570133 | 0.76 | — | — | |
| SCHEMBL31590419 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | disclosed |
| WO-2002018404-A9 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HOFFMANN LA ROCHE (CH) | 2003-10-02 | — | — | WO | disclosed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | disclosed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | NOS3 1775/4885NOS1 2171/4885NOS2 2481/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | NOS3 1775/4885NOS1 2171/4885NOS2 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.